Please share what your organisation and Boehringer Ingelheim will Co-Create together
EtC and BI have the opportunity to co-create a vaccine distribution strategy that will maximize the efficiency and health impact of the vaccine supply chain in underdeveloped countries with an eye towards cost efficiency and sustainability. We envision a real-time inventory management system that monitors vaccines stocks and integrates the supply chain to ensure that sufficient inventory is always in place. By optimizing the cold chain and reaching communities at the last mile, we will broaden distribution of vaccines, into new markets and, subsequently, pave the way to introduce other medications, interventions, and technologies.
If you selected "other" above, please explain:
Please provide a 1-2 sentence summary of your Co-Creation idea
EtC and BI have the opportunity to create a dynamic, comprehensive vaccine program that ensures a reliable, effective, sustainable and scaleable vaccine cold chain, from a country's main port of entry to the patients out in the last mile. With EtC's experience assembling collaborative public-private partnerships and launching our telecom-supported cold chain network, and BI's expertise in supply chain optimizations and logistics, together we can create a more reliable cold chain distribution network that reaches the last mile with greater efficiency and transparency.
How does this project link to the core mission of your organisation?
This project embodies our core mission--to create a vaccine supply chain through strategic public-private partnerships that brings effective vaccines to vulnerable populations, including those in the last mile.
Beyond social impact, how does this project link to Boehringer Ingelheim’s core business?
Like BI, our focus is on creating value through innovation. By leveraging the energy and connectivity of cell towers to power and monitor vaccine refrigerators, we have effectively opened the door to previously inaccessible communities. Our program creates business opportunities by expanding the patient base for vaccines and other therapeutic interventions, accessing new markets. Once distribution channels are established for vaccines into remote areas, we can introduce other medications and technologies into these communities. It is also possible to bring veterinary vaccines into these communities to protect and preserve their livelihood. Healthier communities are also more economically stable and productive, which will further develop potential business opportunities in these regions.
What are the specific inputs and actions that each side will contribute to this Co-Creation idea based on each of your unique competencies and experiences?
EtC will contribute: (1) In-country partnerships with telecom companies, Ministry of Health, USAID, EPI, local health NGOs, University professors and students, and other partners; (2) Expertise in program initiation and launch; (3) Data collections and analysis.
Boehringer Ingelheim will contribute: (1) Expertise in distribution strategy, supply chain optimization, logistsics; (2) Financial support; (3) Coordination of efforts with aligned Making More Health Fellows, which could produce synergies that will broaden access to healthcare in the developing world.
Please describe the potential revenue model for this Co-Creation idea.
EtC is primarily funded through our telecom partner's marketing efforts and related telecom programs. All remaining revenue is received through foundation-based funds for pilot research, health assessments, and operations. Our Co-Creation efforts with BI would support in-country program management, training, and logistical support.
What possible risks or challenges do you foresee?
One of the challenges we face is lack of adequate transportation in-country to link the health centers and health care workers to the children in need of vaccines. Infrastructure is often weak, with few roads, unreliable transportation, and lack of fuel. Another challenge is the lack of a "culture of maintenance" in the countries where we operate, therefore EtC is working to create a maintenance strategy that will optimize equipment and supplies. We also must train health care workers to ensure the new sites are integrated into the existing vaccine program.
Is there anything else you would like to share about your Co-Creation idea?
If you selected "other" above, please explain:
Besides Boehringer Ingelheim, what other types of partners might be valuable to carrying out your Co-Creation idea, and why?
Transportation companies: Many of the countries in need of our prorgam also have limited options for transporation. Whatever vehicles they have are rarely maintained or repaired, and fuel is scarce. Partnering with transportation companies that will lend their expertiese to help solve these problems would be vaulable. This is complicated by poor infrastructure, poor road conditions, and rugged terrain.
Technology companies: We are working on innovative technological solutions to some of the problems related to vaccinating children in these commnities, including infant biometrics for vaccine tracking, to create facial recognition software to better track vaccine records , telecom